• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Kybella (deoxycholic acid)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Kybella (deoxycholic acid)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Kybella (deoxycholic acid) is a non-human and non-animal formulation of deoxycholic acid, a naturally-occurring molecule in the body that aids in the breakdown and absorption of dietary fat. When injected into subcutaneous fat, Kybella causes the destruction of fat cells. Once destroyed, those cells cannot store or accumulate fat. The preference for fat cells leaves surrounding tissue largely unaffected.

    Kybella is specifically indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults.

    Kybella is supplied as an injection for subcutaneous administration. Kybella is injected using an area-adjusted dose of 2 mg/cm2. A single treatment consists of up to a maximum of 50 injections, 0.2 mL each (up to a total of 10 mL), spaced 1-cm apart. Up to 6 single treatments may be administered at intervals no less than 1 month apart.

    Clinical Results

    FDA Approval

    The FDA approval of Kybella was based on two identical randomized, multi-center, double-blind, placebo-controlled trials in healthy adults (ages 19 to 65, BMI ≤ 40 kg/m2 ) with moderate or severe convexity or fullness associated with submental fat. Subjects received up to 6 treatments with Kybella (N=514, combined trials) or placebo (N=508, combined trials) at no less than 1 month intervals. Use of ice/cold packs, topical and/or injectable local anesthesia was allowed during the clinical trials. Injection volume was 0.2 mL per injection site, spaced 1 cm apart into the submental fat tissue, which is also expressed in dose per area as 2 mg/cm2 . For each treatment session a maximum of 100 mg (10 mL) was permitted over the entire treatment area. Subjects were administered an average of 6.4 mL at the first treatment session, and subjects who received all six treatments were administered an average of 4.4 mL at the sixth treatment session. Fifty-nine percent of subjects received all six treatments. The co-primary efficacy assessments were based on at least 2-grade and at least 1-grade improvements in submental convexity or fullness on the composite of clinician-reported and patient-reported ratings of submental fat 12 weeks after final treatment. Reductions in submental fat volume were observed more frequently in the Kybella group compared to the placebo group. 68.2% of subjects responded to Kybella based on a composite of validated physician and patient measurements. Subjects treated with Kybella reported an improvement in the amount of fat in the area under the chin. Subjects also reported improvement in the emotional impact of submental fat when asked how happy, bothered, self-conscious, embarrassed, old and overweight they felt following treatment in relation to the amount of their submental fat.

    Side Effects

    Adverse effects associated with the use of Kybella may include, but are not limited to, the following:

    • injection site edema/swelling
    • hematoma
    • pain
    • numbness
    • erythema
    • induration

    Mechanism of Action

    Kybella (deoxycholic acid) is a non-human and non-animal formulation of deoxycholic acid, a naturally-occurring molecule in the body that aids in the breakdown and absorption of dietary fat. When injected into subcutaneous fat, Kybella causes the destruction of fat cells. Once destroyed, those cells cannot store or accumulate fat. The preference for fat cells leaves surrounding tissue largely unaffected.

    Additional Information

    For additional information regarding Kybella or submental fat, please visit http://mykybella.com/

    Approval Date: 2015-04-01
    Company Name: Kythera Biopharma
    Back to Listings

    Upcoming Events

    • 26Apr

      MAGI's Clinical Research vConference — Spring 2021

    • 06May

      The World of Post-COVID-19 Clinical Trials: How to Prepare for What’s Coming Next

    • 25May

      How Can the Accelerated Availability of Pfizer-BioNTech’s COVID-19 Vaccine be Replicated?

    Featured Products

    • Regenerative Medicine – Steps to Accelerate Development : PDF

      Regenerative Medicine: Steps to Accelerate Development

    • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

      Clinical Trial Agreements: A Guide to Key Words and Phrases

    Featured Stories

    • Bottleneck-360x240.png

      Sites Face Trials Bottleneck After Pandemic, But Also Opportunities

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Genetic Research and IBC Oversight Requirements

    • Inspection-360x240.png

      Pandemic Caused 34 Percent Drop in FDA Investigator Inspections in Fiscal 2020

    • ImproveEfficiency-360x240.png

      Firm Fees, Coordinated Workflows Among Ways Sites Can Improve Efficiency

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing